12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prevnar 13 regulatory update

FDA extended the review period by three months for an sBLA from Pfizer for its Prevnar 13 pneumococcal vaccine to January 2012 from October. Pfizer is seeking accelerated approval to expand the label to include prevention...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >